HK1246677B - 治療癌症的耐藥性免疫療法 - Google Patents

治療癌症的耐藥性免疫療法

Info

Publication number
HK1246677B
HK1246677B HK18106297.7A HK18106297A HK1246677B HK 1246677 B HK1246677 B HK 1246677B HK 18106297 A HK18106297 A HK 18106297A HK 1246677 B HK1246677 B HK 1246677B
Authority
HK
Hong Kong
Prior art keywords
cancer
treatment
drug resistant
immunotherapy
resistant immunotherapy
Prior art date
Application number
HK18106297.7A
Other languages
English (en)
Inventor
H Trent Spencer
Anindya Dasgupta
Lawrence S Lamb
Original Assignee
Univ Emory
Childrens Healthcare Atlanta Inc
Uab Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory, Childrens Healthcare Atlanta Inc, Uab Res Found filed Critical Univ Emory
Publication of HK1246677B publication Critical patent/HK1246677B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK18106297.7A 2009-11-02 2018-05-15 治療癌症的耐藥性免疫療法 HK1246677B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25713609P 2009-11-02 2009-11-02

Publications (1)

Publication Number Publication Date
HK1246677B true HK1246677B (zh) 2020-06-05

Family

ID=43922989

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18106297.7A HK1246677B (zh) 2009-11-02 2018-05-15 治療癌症的耐藥性免疫療法

Country Status (6)

Country Link
US (4) US20120258532A1 (zh)
EP (4) EP3970736A1 (zh)
DK (1) DK3246042T3 (zh)
ES (3) ES2633098T3 (zh)
HK (1) HK1246677B (zh)
WO (1) WO2011053750A2 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2643387T3 (es) 2011-05-19 2017-11-22 Instituto De Medicina Molecular Estirpe celular de linfocitos que comprende células gama-delta, composición y método de producción de la misma
CA2868439C (en) 2012-03-28 2023-09-26 Umc Utrecht Holding B.V. Combinatorial gamma 9 delta 2 t cell receptor chain exchange
WO2014191128A1 (en) * 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
JP2019047801A (ja) * 2013-05-29 2019-03-28 セレクティスＣｅｌｌｅｃｔｉｓ Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法
JP6976058B2 (ja) 2013-11-22 2021-12-01 セレクティスCellectis 免疫療法のための化学療法薬耐性ｔ細胞を工学的に作製する方法
ES2792849T3 (es) 2014-02-10 2020-11-12 Univ Emory Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer
EP3804741A3 (en) * 2015-02-24 2021-07-14 Board of Regents, The University of Texas System Selection methods for genetically-modified t cells
US12005078B2 (en) * 2015-09-03 2024-06-11 The Uab Research Foundation Genetically engineered drug resistant T cells and methods of using the same
EP3469362A1 (en) 2016-06-10 2019-04-17 Gadeta B.V. Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof
EP3500262A4 (en) * 2016-08-18 2020-03-25 The UAB Research Foundation COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY
US11421005B2 (en) * 2016-12-09 2022-08-23 The Uab Research Foundation Chimeric chlorotoxin receptors
WO2019051135A1 (en) 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center METHODS FOR IMPROVING ADOPTIVE CELL THERAPY
WO2023021113A1 (en) * 2021-08-18 2023-02-23 Julius-Maximilians-Universität Würzburg Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199398T1 (de) * 1989-10-24 2001-03-15 Chiron Corp Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein
WO1997032025A1 (en) * 1996-03-01 1997-09-04 Regents Of The University Of Minnesota Method for selective engraftment of drug-resistant hematopoietic stem cells
US7078034B2 (en) 1999-01-28 2006-07-18 Palmetto Health Alliance In vitro activated γ δ lymphocytes
US8066989B2 (en) * 2004-11-30 2011-11-29 Trion Pharma Gmbh Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy
US8445264B2 (en) 2011-04-08 2013-05-21 Rarecyte, Inc. Systems and methods for harvesting target particles of a suspension
US20160024175A1 (en) 2013-03-10 2016-01-28 Baylor College Of Medicine Chemotherapy-resistant immune cells
ES2792849T3 (es) 2014-02-10 2020-11-12 Univ Emory Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer
US12005078B2 (en) 2015-09-03 2024-06-11 The Uab Research Foundation Genetically engineered drug resistant T cells and methods of using the same

Also Published As

Publication number Publication date
EP3246042B1 (en) 2019-07-10
DK3246042T3 (da) 2019-10-14
US10543233B2 (en) 2020-01-28
EP2496244A4 (en) 2013-09-18
US10322145B2 (en) 2019-06-18
ES2633098T3 (es) 2017-09-19
US20120258532A1 (en) 2012-10-11
US20200323903A1 (en) 2020-10-15
US20150017137A1 (en) 2015-01-15
WO2011053750A2 (en) 2011-05-05
ES2743507T3 (es) 2020-02-19
EP3970736A1 (en) 2022-03-23
EP3552617A1 (en) 2019-10-16
ES2882916T3 (es) 2021-12-03
US20190175653A1 (en) 2019-06-13
EP3246042A1 (en) 2017-11-22
EP3552617B1 (en) 2021-07-07
WO2011053750A3 (en) 2011-09-22
EP2496244B8 (en) 2017-11-08
EP2496244A2 (en) 2012-09-12
EP2496244B1 (en) 2017-04-12

Similar Documents

Publication Publication Date Title
HK1246677B (zh) 治療癌症的耐藥性免疫療法
IL219073A (en) A drug combination for cancer treatment
IL218575A0 (en) Treatment of cancer
PL2482849T3 (pl) Skojarzona immunoterapia w leczeniu nowotworu
HK1175476A1 (zh) 癌症治療
EP2542081A4 (en) COMPOSITIONS FOR CANCER TREATMENT
SG10201508495VA (en) Combination treatment of cancer
EP2470200A4 (en) CYTOTOXIC T-LYMPHOCYTE INDUCTIVE IMMUNOGENES FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF CANCER
IL213761A0 (en) Novel ortho-aminoamides for the treatment of cancer
GB0910723D0 (en) Novel drugs for inhibition of gene expression
IL275350B (en) Treatment of neoplastic diseases
EP2544692A4 (en) USE OF TIGECYCLINE FOR THE TREATMENT OF CANCER
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
IL222958A0 (en) Cancer treatment
EP2608671A4 (en) COMPOUNDS USED IN THE TREATMENT OF CANCER
ZA201109514B (en) Method of drug delivery
ZA201202169B (en) Targeting pax2 for the treatment of breast cancer
IL215037A0 (en) Treatment of pancreatic cancer
EP2403341A4 (en) LUNGENKREBSBEHNDLUNG
ZA201202379B (en) Antagonists of dsgs2 for treatment of cancer
ZA201201894B (en) Pharmaceutical combination for treating tumor
EP2473613A4 (en) KREBSAUSHUNGERUNGSTHERAPIE
EP2755679A4 (en) IMMUNOGENS INDUCING CYTOTOXIC T LYMPHOCYTES FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF CANCER
GB0921757D0 (en) Treatment of cancer
GB0906490D0 (en) Use of tetanolic for treatment of breast cancer